Radiopharm Theranostics Limited RADX
0.84 USD -0.04 (-4.75%)
At closeNov 10, 2026, 4:00 PM EST
0.85 +0.01 +0.83%
After hours · Nov 10, 4:00 PM ET
0.843 Day range 0.9419
0.843 52-week range 10.63
- YTD
- -83.85%
- 1 year
- -83.00%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…
globenewswire.com Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases Single, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholds
globenewswire.com Radiopharm Theranostics Reports Business Update Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug Administration
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
benzinga.com Radiopharm Theranostics Announces Completion Of EOP2 Meeting With FDA Regarding RAD101, Investigational Radiopharmaceutical Imaging Agent For Detection Of Brain Metastases Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imagingCurrently executing Phase 3 readiness activities in anticipation of FDA…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…
benzinga.com Radiopharm Says Data From Interim Analysis Of Phase 2b Imaging Clinical Trial Of 18F-RAD101 In Participants With Suspected Recurrent Brain Metastases From Solid Tumors Selected For Presentation At SNO26 Annual Meeting RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpointMeeting with FDA planned on October 1st to align on RAD101Phase 3 pivotal trial…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX)…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre-market session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma…
- benzinga.com Radiopharm Theranostics Shares Data From Phase 1 Imaging Trial of RAD 301 In Healthy Volunteers And Subjects With Pancreatic Ductal Adenocarcinoma RAD301 is a peptide-based molecule bound to Gallium-68 (Ga-68) that targets αvβ6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with…
globenewswire.com Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting…
benzinga.com Radiopharm Doses First Patient In Second Cohort Of Its First-In-Human Phase 1/2a Clinical Trial Of RV-01 In Patients With B7-H3 Expressing Tumors Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of…
globenewswire.com Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company's joint venture with MD Anderson Cancer Center Doses first patient at 70 mCi dose of RV-01,…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-market session. The company's market cap stands at $6.5 million. As per the press release, Q2 earnings…
defenseworld.net Radiopharm Theranostics (NASDAQ:RADX) Trading Down 8.4% – What’s Next? Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report)'s share price traded down 8.4% during mid-day trading on Thursday. The stock traded as low as $2.23 and last traded at…
globenewswire.com Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated…- benzinga.com Radiopharm Theranostics Schedules An FDA End-Of-Phase 2 For October 1, 2026, To Align On The Design Of A Pivotal Phase 3 Trial To Evaluate RAD101 In Patients With Suspected Recurrence Of Brain Metastases Following Radiotherapy RAD101 is the Company's novel Fluorine-18-labeled small-molecule imaging agent that targets fatty acid synthase (FASN) and is being developed to diagnose suspected recurrent brain metastases arising…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday's pre-market session. The company's market cap stands at $1.4 million. OneMedNet (NASDAQ:ONMD) shares…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular session. The market value of their outstanding shares is at $17.4 billion. The company's, Q2 earnings…
benzinga.com US Stocks Mixed; American Express Shares Fall Following Q2 Results US stocks mixed, Dow Jones up 0.2%. Real estate shares up 1.3%. American Express falls 6%. Ohmyhome, LiveWire, Vivakor surge. Robin Energy, RADIOPHARM, Codexis down.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 28.3% to $21.53 during Friday's pre-market session. The company's market cap stands at $27.4 million. Akanda (NASDAQ:AKAN) shares…
benzinga.com Radiopharm Theranostics Announces $4.1M U.S. Direct Offering Of Shares And Warrants Along With A$12.7M ($8.9M) Australian Placement Radiopharm Theranostics Limited (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for…
globenewswire.com Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on…
benzinga.com Radiopharm Theranostics Announces Updated Clinical Results From First Two Patients In Third Cohort Of RAD204; First RECIST-Confirmed Durable Partial Response At Current Highest Dose Level #3, With Patient Progression Free Beyond Seven Months Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatmentRAD204 is generally well-tolerated with no dose-limiting toxicities…- benzinga.com Radiopharm Theranostics Announces Data From All Thirty Evaluable Patients In Its Phase 2B Trial Of RAD101 In Participants With Suspected Recurrence Of Brain Metastases After Radiotherapy; RAD101 PET Demonstrated 93% Concordance With MRI Across All Evaluable Lesions, Meeting The Primary Endpoint 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.The Company plans to…
globenewswire.com Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months
globenewswire.com Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares…
benzinga.com This HC Wainwright & Co. Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday Wall Street analysts began coverage on top names, including a bullish rating on Radiopharm Theranostics. See more analyst ratings.
benzinga.com HC Wainwright & Co. Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $16 HC Wainwright & Co. analyst Robert Burns initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and announces Price Target of $16.
benzinga.com Radiopharm Theranostics Issues Business Update Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of…
globenewswire.com Radiopharm Theranostics Reports Business Update Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI…- benzinga.com Radiopharm Theranostics Announces That New Data From The Ongoing Phase 0/1 Heat Trial Evaluating 177Lu-RAD202, A First-In-Class HER2-targeted Radiopharmaceutical Therapy, Will Be Presented As A Poster At The American Association For Cancer Research Annual Meeting on April 17–22 Key Findings from the AACR Abstract and PosterMeaningful tumor uptake of 177Lu-RAD202 was observed at the initial and lowest dose level of 30 mCi, particularly in breast cancer lesions177Lu-RAD202…
- benzinga.com Radiopharm Announces Dosing Of Final Patient In Phase 2b Imaging Trial Evaluating RAD 101 In Individuals With Confirmed Recurrent Brain Metastases From Solid Tumors Of Different Origins The U.S. multicenter, open-label, single arm Phase 2b clinical trial is evaluating the diagnostic performance of 18F-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid…
- benzinga.com Radiopharm Theranostics Advances Cancer Drug Trial After Safety Review Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of…
globenewswire.com Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI.- benzinga.com Radiopharm Theranostics Says First Patient Dosed In First-In-Human Phase 1 Clinical Trial Of RAD 402, Monoclonal Antibody Targeting KLK3 Radiolabelled With Terbium 161 Being Evaluated In Advanced Prostate Cancer On track to share data from first two dose levels in 2H 2026Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate CancerPreclinical…
globenewswire.com Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer…
proactiveinvestors.com Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF, NASDAQ:RADX) has dosed the first patient in a Phase 1 clinical trial of its lead prostate cancer candidate...
proactiveinvestors.com Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF, NASDAQ:RADX) has dosed the first patient in a Phase 1 clinical trial of its lead prostate cancer candidate...
defenseworld.net Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study Radiopharm Theranostics (NASDAQ: RADX) executives and clinical investigators highlighted new interim findings from the company's ongoing Phase IIb study of RAD101, a PET imaging tracer intended to…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results RAD 101 is Radiopharm's novel, small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from…
benzinga.com Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results Radiopharm Theranostics says Phase 2b interim data showing 90% MRI concordance for RAD 101, with final readout expected by June.- benzinga.com Radiopharm Drug Shows 90% Accuracy In Detecting Brain Tumors In Trial Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet…
defenseworld.net Financial Comparison: Biodexa Pharmaceuticals (NASDAQ:BDRX) versus Radiopharm Theranostics (NASDAQ:RADX) Radiopharm Theranostics (NASDAQ: RADX - Get Free Report) and Biodexa Pharmaceuticals (NASDAQ: BDRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will…
defenseworld.net Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Average Rating of “Buy” by Brokerages Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report) have been given an average recommendation of "Buy" by the five analysts that are covering the firm,…